This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Spanish to English - Rates: 0.08 - 0.90 USD per word / 25 - 30 USD per hour English to Spanish - Rates: 0.08 - 0.90 USD per word / 25 - 30 USD per hour Italian to English - Rates: 0.08 - 0.90 USD per word / 25 - 30 USD per hour Portuguese to English - Rates: 0.08 - 0.90 USD per word / 25 - 30 USD per hour
Spanish to English: Medical: Clinical History/Medical Records General field: Medical Detailed field: Medical (general)
Source text - Spanish INFORME DE ALTA HOSPITALARIA
NEUMOLOGÍA
DIAGNÓSTICO PRINCIPAL
■ INFECCIÓN RESPIRATORIA
OTROS DIAGNÓSTICOS
EPOC SEVERO LOS PREVIOS
MOTIVO DE INGRESO
FIEBRE, DISNEA
ANTECEDENTES
No RAM conocidas. No dislipemia. Hipertensión arterial, Diabetes mellitus tipo 2. Hipertiroidismo diagnosticado en 3005 sin tratamiento en la actualidad por normalización de hormonas tiroideas (en seguimiento por Endocrinología). Ex-fumador de 80 años/paquete. EPOC conocido con múltiples ingresos en nuestra Sección por agudización de su patología de base, último en marzo 2005. En seguimiento en nuestra consulta externa. Dos ingresos previos en UCI con necesidad de ventilación mecánica no invasiva. Tromboembolismo pulmonar en 1996,- Cardiopatía isquémica crónica con angioplastía hace 13 años. Claudicación intermitente- AQ: amputación de 2 dedos del pie izado., prótesis de cadera derecha, cataratas, hemorroidectomía. Independiente para las actividades de la vida diaria. Clase funcional II/IV para la disnea. Tratamiento medico: Hemovas, Teromol Retard, Aldactone, Sintrom, Seguril, Seretide, Spiriva, Novomix,
ENFERMEDAD ACTUAL
Varón de 70 años que presenta desde hace 45 días tos con expectoración blanquecina. En las últimas 48 horas presenta además disnea progresiva hasta hacerse de reposo así como febrícula. No dolor torácico. Habla iniciado tratamiento con Tavanic y Dacortin, pero ante el empeoramiento clínico acudió a Urgencias.
EXPLORACIÓN CLÍNICA
TA 80/60. FC 84 lpm. 39,4°C, FR 16 rpm, saturación 968 respirando aire ambiente. Buen estado general. No ingurgitación yugular. AC: rítmica. AP: roncos y sibilantes diseminados en ambos hemitórax. Abdomen: anodino. MMII: no edemas, no signos de TVP, pulsos conservados.
EXPLORACIONES COMPLEMENTARIAS.
RX DE TÓRAX: signos de hiperinsuflación pulmonar, no signos de insuficiencia cardíaca, no condensaciones, cambios de aspecto inflamatorio crónico en ambas bases.
GASOMETRÍA ARTERIAL BASAL (FiO2 21%): PH 7.48, PC02 34, P02 75, HC03 25, SAT HEMOGRAMA: 14.800 leucos con 83.6%. Hb 13.5. Hto 39.8%. Plaquetas 167.000.
COAGULACIÓN: TP 25.6, IQ 34%. APTT 39.9. BIOQUÍMICA: glucosa 27. PT 5.03. Alb 3.45. colesterol 97. K 5.98. resto normal. HORMONAS TIROIDEAS: T4 0.90. TSH 1.22. GASOMETRÍA ARTERIAL:(FiO2 desconocida) PH 7.48. PC02 34.1. PO2 75.4
HCO3 25.2. '
ECG: RS a 100 lpm. Eje a 85°. PR normal. Q en III PRUEBAS FUNCIONALES: FVC 2050 (52%). FEVl 940 (34%). IT 46 (85%). VOLÚMENES: TLC 4950 (84%). VC 2090 (53%). VR 2860 (119%).
Translation - English HOSPITAL DISCHARGE SUMMARY
PNEUMOLOGY
MAIN DIAGNOSIS
RESPIRATORY INFECTION
OTHER DIAGNOSES
SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
AS ABOVE
REASON FOR ADMISSION
TEMPERATURE, DYSPNOEA
CLINICAL HISTORY
No known Adverse Reactions to Medications. No dyslipidaemia. Arterial hypertension, Type 2 Diabetes Mellitus. Hypothyroidism diagnosed in 2005 under no current treatment due to thyroid hormone normalisation (followed-up by Endocrinology). Ex-smoker of 80 packs/year. Known Chronic Obstructive Pulmonary Disease (COPD) with multiple admissions in our Department for impairing of basal pathology, last in March 2005. Followed-up by our Outpatient’s Department. Two previous admissions in Intensive Care Unit requiring non-invasive mechanical respiration. Pulmonary Thromboembolism in 1996, Chronic Ischaemic Cardiopathy with angioplasty 13 years ago. Intermittent Claudication-. Surgical History: Amputation of 2 toes of left foot, left hip prosthesis, cataract, haemorroidectomy. Independent for daily activities. Functional class II/IV for dyspnoea. Medical treatment: Hemovas, Teromol Retard, Aldactone, Sintrom, Seguril, Seretide, Spiriva, Novomix.
PRESENTING COMPLAINT
70-year-old male patient presenting cough with whitish sputum. Within the last 48 hours the patient also reports progressive dyspnoea , which turmed into dyspnoea at rest as well as slight temperature. No chest pain. Treatment with Tavanic and Dacortin had been initiated, but due to impairment, the patient was admitted at A&E.
CLINICAL EXAMINATION
Blood Pressure (BP) 80/60. Cardiac Frequency (CF): 84 bmp 39.4°C, Respiratory Frequency (RF) 16 rmp, saturation 96% breathing room temperature air. Good general conditions. No jugular distension. Cardiac Auscultation (CA): Rhythmical. Pulmonary Auscultation (PA): rhonchi and wheezing spread all over both hemithorax. Abdomen: anodyne. Lower Limbs: No oedemas, no signs of Deep Venous Thrombosis (DVT), conserved pulses.
OTHER INVESTIGATIONS
CHEST X-RAY: Sings of pulmonary hyper-insufflation, no signs of cardiac insufficiency, no condensations, chronic inflammatory changes on both bases. ARTERIAL BASAL GASOMETRY (Fractional Inspired Oxygen [FIO2] 21%): pH 7.48, Carbon Dioxide Partial Pressure (PCO2) 34, Oxygen Partial Pressure (P02) 75, Bicarbonate (HC03) 25, Oxygen Saturation (O2 Sat) 95.7%.
HAEMOGRAM: 14,800 leukocytes with 83.6%. Haemoglobin 13.5. Haematocrit 39.8%. Platelets 167,000.
COAGULATION: Prothrombin Time (PT) 25.6, Quick’s Index (QI) 34%. Activated Partial Thromboplastin Time (APTT) 39.9. BIOCHEMISTRY: Glucose 273. Total Proteins (TP) 6.03. Albumin 3.45. Cholesterol 97. Potassium (K) 5.98. Rest of results: normal. THYROID HORMONES: T4 0.90. Thyroid Stimulating Hormone (TSH) 1.22. ARTERIAL GASOMETRY (unknown Fractional Inspired Oxygen [FIO2]): pH 7.48. Carbon Dioxide Partial Pressure (PCO2) 34.1. Oxygen Partial Pressure (P02) 75.4, Bicarbonate (HC03) 25.2. '
ELECTROCARDIOGRAM (ECG): Sinus Rhythm at 100 bpm. Axis: 85°. PR index: normal. Q in III.
FUNCTIONAL TESTS: FVC (Forced Vital Capacity) 2050 (52%). Forced Expiratory Volume (FEV1): 940 (34%). Temporary Incapacity (TI) 46 (85%). VOLUMES: Total Lung Capacity 4950 (84%). Vital Capacity (VC) 2090 (53%). Respiratory Volume (RV) 2860 (119%).
Spanish to English: CLINICAL TRIALS/Approval for conduction General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - Spanish AUTORIZACIÓN PARA EL DESARROLLO DE ESTUDIOS CLÍNICOS
4.1 Criterio de inclusión
4.1.1 Antes de iniciado cualquier procedimiento específico de estudio, debe obtenerse el debido consentimiento por escrito (ver Sección 12.1).
4.1.2 18 años de edad al momento de selección aleatoria.≥
4.1.3 a 3 meses, y de clase II, III o IV (NYHA) al momento de selección aleatoria.≥Insuficiencia cardíaca (IC)
40% en≤4.1.4 Fracción de Eyección de Ventrículo Izquierdo ecocardiograma, ventriculografía por radioisótopos, imagen de resonancia magnética cardíaca, o ventriculografía de contraste por Rayos X dentro de un período de 6 meses previos a la selección aleatoria. Los pacientes en terapia de resincronización cardíaca serán elegibles solo luego de someterse a evaluación de la Fracción de Eyección de Ventrículo Izquierdo en al menos 3 meses posteriores al implante del dispositivo.
a 12,0≤ a 9,0 g/dL y ≥4.1.5 La concentración de hemoglobina debe ser g/dL (promedio de 2 concentraciones de hemoglobina medidas por estudio ciego con HemoCue® [codificado]).
4.1.6 En tratamiento de IC (insuficiencia cardíaca) con terapia farmacológica estable y óptima. En general, un tratamiento óptimo incluirá un betabloqueante y un inhibidor ACE y/o un ARB (bloqueador de receptor de angiotensina) en dosis eficaces para estudios sobre insuficiencias cardíacas, salvo que no sean toleradas. La terapia médica estable se establece al no introducir nuevas drogas para tratamiento de insuficiencias cardíacas en un período de 4 semanas previo a la selección aleatoria, aunque las dosis de aquellas drogas que estén administrándose se ajustarán a lo largo del estudio. Directivas generales para el tratamiento óptimo de insuficiencias cardíacas se detallan en el Apéndice J.
4.2 Criterio de exclusión
4.2.1 Control insuficiente de hipertensión, definido por una tensión arterial > 160/100 mm Hg medida en dos ocasiones separadas previo a la selección aleatoria.
4.2.2 Creatinina sérica > 3.0 mg/dL (> mol/L)μ265
4.2.3 Insuficiencia cardíaca primordialmente asociada a enfermedad cardíaca valvular o enfermedad cardíaca valvular de relevancia clínica que pueda requerir intervención quirúrgica correctiva dentro de los 12 meses de selección aleatoria.
4.2.4 Desfribilador Cardioversor Implantable (DCI) dentro de los 30 días previos a la selección aleatoria o iniciación de terapia de resincronización cardíaca (TRC con o sin DCI) dentro de los 3 meses previos a la selección aleatoria.
4.2.5 Aplicaciones intravenosas efectuadas regularmente para IC (Ej.: inotrópicos, vasodilatadores (Ej.: Nesiritida), diuréticos).
4.2.6 Infarto agudo de miocardio o accidente cerebrovascular dentro de los 3 meses previos a la selección aleatoria.
4.2.7 Intervención percutánea (cardíaca, cerebrovascular, aórtica) dentro de los 8 meses previos a la selección aleatoria. Cirugía mayor, incluyendo cirugía torácica o cardíaca, dentro de los 3 meses previos a la selección aleatoria.
Translation - English APPROVAL FOR CONDUCTION OF CLINICAL STUDIES
4.1 Inclusion Criteria
4.1.1 Before any study-specific procedure, the appropriate written informed consent must be obtained (see Section 12.1).
4.1.2 18 years of age at the time of randomization≥
4.1.3 3 months, and of NYHA class II, III or IV at the time of randomization.≥Heart failure for
40% by echocardiogram,≤4.1.4 Left ventricular ejection fraction radionuclide ventriculography, cardiac magnetic resonance imaging, or X-ray contrast ventriculography within 6 months prior to randomization. For patients with CRT, LVEF assessment for eligibility must be performed at least 3 months after device implantation.
12.0 g/dL≤ 9.0 g/dL and ≥4.1.5 Hemoglobin concentration must be (average of 2 hemoglobin concentrations as measured by blinded [coded] HemoCue® analyzer).
4.1.6 Treated for HF with stable, optimal pharmacological therapy. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an ARB at doses shown to be efficacious in HF trials, unless not tolerated. Stable medical therapy is defined as having no new HF drug class introduced 4 weeks prior to randomization, although doses of all drugs being received may be adjusted throughout the trial. General guidelines for optimal HF treatment are provided in Appendix J.
4.2 Exclusion Criteria
4.2.1 Poorly controlled hypertension, defined as blood pressure > 160/100 mm Hg assessed on two separate occasions prior to randomization
4.2.2 Serum creatinine > 3.0 mg/dL (> mol/L)μ265
4.2.3 Heart failure primarily due to valvular heart disease or clinically significant valvular heart disease that might lead to surgical correction within 12 months of randomization
4.2.4 Implantable cardioverter defibrillator (ICD) within 30 days prior to randomization or initiation of cardiac resynchronization therapy (CRT with/without ICD) within 3 months prior to randomization
4.2.5 Routinely scheduled IV infusions for HF (eg, inotropes, vasodilators [eg, nesiritide], diuretics)
4.2.6 Acute myocardial infarction or cerebrovascular accident within 3 months prior to randomization
4.2.7 Percutaneous intervention (cardiac, cerebrovascular, aortic) within 8 weeks prior to randomization. Major surgery, including thoracic or cardiac surgery, within 3 months prior to randomization
Italian to English: Medical: Records/Clinical Histories General field: Medical Detailed field: Medical (general)
Source text - Italian Divisione di Cardiologìa Primario: Prof. S. Chierchta
DAY HOSPITAL
Pregresso IMA. Pregressi interventi coronarici percutanei. Coronaropatia ostruttiva.
Intervento coronarico percutaneo.
Motivo del ricovero
Coronarografìa
Dati Anamnestici
Ipertensione arteriosa, diabete mellito tipo I, dislipidemia, ex fumatore, sovrappeso, lieve IRC
Nega allergie o intolleranze a farmaci.
1982 IMA. 1998 ricovero per angina instabile.
2000 ricovero per angina instabile con riscontro coronarografico di stenosi di Iva media con
trombosi endoluminale, stenosi critica di ramo secondario di ramo diagonale, stenosi 90% di esile
JYP da CX . Proseguita terapia medica per 3 giorni e persistendo instabilita1 clinica il paz. veniva
sottoposto a Ptca Stent su IVA media.
3/2001 ricovero per angina a riposo, riscontro coronarografico di restenosi intra-stent trattata
mediante PTCA, coesite malattia dì rami secondari di IVA e CX.
Ultimo test ergometrico 15/11/2001 con riscontro di modificazioni ECG asintomatiche ad elevato
carico lavorativo in presenza di elevati valori pressori.
AH'ecocardiogramma ventricolo sinistro dilatato, ipertrofico con alterazioni della cinesi regionale
in sede settale ed inferiore. Moderata compromissione della funzione sistolica globale (FÉ 40%).
Lieve insufficienza mitro aortica.
Da circa 1 anno parestesie alla mano destra con ipotrofia muscolare.
Da circa 1 settimana riferisce dolori interscapolari da sforzo a regressione con il riposo, veniva
quindi consigliata coronarografìa.
Descrizione del Ricovero
Entra in reparto in buone condizioni di nutrizione e sanguificazione, non cianosi né edemi. Cute calda e asciutta. PA160/90, 70 fc /min. Toni cardiaci netti, ritmici, impurità sisto-diastolica. Polsi periferici eusfigmici e simmetrici. MV aspro.Edemi declivi , Addome globoso, trattabile, non dolente né dolorabile. Organi ipocondriaci non palpabili.
In data 22/11/2004 è stato eseguito esame coronarografico con riscontro di (Vd referto) persistente buon risultato angiografico in sede di pregressa PTCA su IVA media, con progressione di malattia sul tratto prossimale. Ostio critico di ramo diagonale. Subocclusione di 1VP di CX dominante, occlusione di CDx ipoplasica. E' stata quindi eseguita PTCA ed impianto di stent medicato su IVA prossimale.
Visti i valori di creatinina è stata intrapresa opportuna terapia di reidratazione aceti 1-cisteina.
Gli esami ematochimici eseguiti sono risultati nella norma ad eccezione di (vd allegato): glicemia, azotemia, creatinina, uricemia, CPK.
Translation - English Department of Cardiology Head Physician: Prof. S Chierchia. DAY HOSPITAL
Improvement of Acute Myocardial Infarction. Improvement from Percutaneous Coronary intervention. Obstructive Cardiopathy.
Percutaneous Coronary Intervention.
Reason for discharge.
Coronary Angiography
Clinical History
Arterial Hypertension, Type 1 Diabetes Mellitus, Dyslipidaemia, Ex Smoker, Overweight, mild Renal Chronic Insufficiency.
Denies allergies or intolerance to medication.
Acute Myocardial Infarction in 1982. Admission in 1998 due to unstable angina.
Admission in 2000 due to unstable angina with findings through coronary angiography of stenosis of mean Anterior Interventricular Artery with eee ndoluminal thrombosis, severe stenosis of secondary diagonal branch, stenosis of 90% of Posterior Interventricular Artery from Circumflex Coronary Artery. Clinical therapy followed up for 3 days and due to persistence of clinical instability the patient is performed Percutaneous Transluminal Coronary Angioplasty (PTCA) plus Stent on mean Anterior Interventricular Artery.
In March 2003 the patient is admitted due to angina at rest, findings from coronary angiography reveal intra-Stent stenosis treated through Percutaneous Transluminal Coronary Angioplasty (PTCA) of Anterior Interventricular Artery and Circumflex Coronary Artery.
Last ergometric test on 15/11/2001 which revealed modifications Echocardiogram asymptomatic upon high
Amount of effort in presence of high blood pressure values.
On echocardiogram: dilated left ventricle, hypertrophied with alterations of the regional kinesis
on septal and inferior areas. Moderate impairment of global systolic function (Ejection Fraction 40%)
Mild Mitral-Aortic Insufficiency.
Right hand paraesthesia of approximately 1 year with muscular hypotrophy.
Since approximately 1 week patient reports interscapular pain on exertion in regression with at rest, therefore it is suggested coronary angiography.
Reasons for admission
Patient is admitted in good nutritional and haemodynamic conditions, no cyanosis nor oedemas. Skin hot and dry. Blood Pressure 160/90. Cardiac frequency 70/min. Cardiac sounds clear, rhythmical, sisto-diastolic impurity. Peripheral pulses eusfigmici and symmetric. Rasping Vesicular Murmurs. Oedema decrease . Abdomen: Round, indentable, non painful on palpation. Hypochondriac organs not palpable.
On 22/11/2004 patient is performed coronary angiography which findings reveal (refer to report) persistent good results fron coronary angiography over Percutaneal Transluminal Coronary Angioplasty (PTCA) on mean Anterior Interventricular Artery, with improvement of disease upon the proximal tract. Critical ostium upon diagonal branch. Sub-occlusion of Posterior Interventricular Artery of main Circumflex Artery, occlusion of Right Coronary Artery. It is therefore performed Percutaneal Transluminal Coronary Angioplasty (PTCA) and implantation of Stent administered upon proximal Anterior Interventricular Artery.
The values of creatinine are checked and due re-hydration therapy is undertaken with acetil-cisteina.
The performed haematology examinations show results with the exception of (refer to attached report): Glycaemia, Aztaemia, Creatinine, Uricaemia, Creatine Phosphokinase (CPK).
Italian to English: Legal: Agreements/Acts General field: Law/Patents Detailed field: Law: Contract(s)
Source text - Italian OGGETTO SOCIALE
Articolo 4.
La Società ha per oggetto la ricerca, l’elaborazione, la gestione e la prestazione di servizi, anche informatici e telematici, per conto e/o in favore di soggetti pubblici e/o privati, Enti locali ed soggetti ad essi assimilati, in conformità alle disposizioni di legge vigenti, nonché ogni attività connessa o complementare o, comunque, indirizzata al supporto della predisposizione ed attuazione dei predetti servizi.
La Società potrà inoltre svolgere, su richiesta di Enti locali o soggetti pubblici o privati interessati, l’attività di liquidazione ed accertamento dei tributi e di altre entrate, unitamente allo svolgimento di attività di riscossione consentite dalla legge, ivi compresa l’attività di recupero crediti ed ogni attività connessa o complementare; potrà altresì svolgere ogni operazione mobiliare, immobiliare, commerciale e finanziaria direttamente o indirettamente utile per il conseguimento dell’oggetto sociale, anche mediante l’assunzione partecipazioni in società o aziende aventi scopi diversi da quelli sopra descritti, purché in conformità a quanto disposto nell’art. 2361 cod. civ.
CAPITALE ED AZIONI SOCIALI
Articolo 5.
Il capitale sociale è di L. 3.000.000.000 (tremiliardi), diviso in n. 3.000.000 azioni ordinarie del valore nominale di L. 1.000 ciascuna.
Ogni azione ordinaria attribuisce il diritto ad un voto.
Qualora la Società fosse iscritta all’Albo di cui al D.M. Finanze 11 settembre 2000 n. 289, il trasferimento di azioni per atto tra vivi, ivi compresi gli atti di fusione e di scissione, è soggetto, a pena di inefficacia, alla preventiva autorizzazione del Ministero delle finanze, in conformità alle disposizioni di legge in materia, ed in mancanza non potrà essere annotato nel libro soci.
Translation - English SOCIAL OBJECTIVE
Article 4.
The company’s objective involves the research, processing, management and provision of services, both computerized and telematic, in regard to and/or in favor of public and/or private subjects, local administration entities and the subjects thereto related, in compliance with current regulations, as well as any connected or complementary activity or otherwise intended to support the preparation and implementation of the above-mentioned services.
The company might in addition perform, at request of the interested public or private subjects, clearance activities and determination of charges and other revenue, together with the levying activities permitted by law, including credit recovery and any connected or complementary activities; it might also carry out any operation concerning movable property, real estate property, commercial and financial activities directly or indirectly functional for the fulfilment of the social objective, as well as through the acquisition of shareholdings in companies or firms whose purposes are other than those described above, as stipulated in compliance with art. 2361 of Civil Code.
SOCIAL CAPITAL AND SHARES
Article 5.
The social capital is of L3,000,000,000 (three billion), divided into 3,000,000 ordinary shares with a nominal value of L1, 000 each.
Each ordinary share entitles the right to one vote.
Should the company bear registration in reference to Department of Finances Decree No.289 September 2000, the transference of shares by means of the living, including acts of merging and division therein, is subject to, unless proven inefficient, the prior authorization of the Department of Finances, in compliance with due pertinent regulations, the lack of which will result in the impossibility of being registered upon the shareholder’s register.
Spanish to English: Law: Quality Standardization Agreement General field: Law/Patents Detailed field: Electronics / Elect Eng
Source text - Spanish DECLARACION DE CONFORMIDAD
MANUAL DE CONTROL
DE CALIDAD
Destinado a:
CUMPLIMIENTO DE LA DIRECTIVA 2006/95/CE del
PARLAMENTO EUROPEO Y DEL CONSEJO
RELATIVO A
LEGISLACION SOBRE EL MATERIAL ELECTRICO
1.- METODOLOGÍA DE CONTROL
Este documento, cumplimenta el ANEXO I, de la Directiva 2006/95/CE “Principales Elementos De Los Objetivos De Seguridad Sobre El Material Eléctrico Destinado A Utilizarse Con Determinados Límites De Tensión.”
Se aplicará a los materiales, productos o equipos, ejecución de los servicios, ingeniería ejecutiva, procesos de montaje / constructivos que se requieran, a saber:
Los objetivos a cumplimentar buscan que las instalaciones dispongan de un servicio eficaz y eficiente, en los aspectos contractuales, operación, seguridad operativa y mantenimiento.
1.1.- INTRODUCCIÓN: REQUISITOS A CUMPLIR, de acuerdo al Anexo I de la Directiva 2006/95/CE del PARLAMENTO EUROPEO Y DEL CONSEJO relativo a legislación sobre el material eléctrico, PROYECCION ELECTROLUZ SRL, establece, documenta, aplica y mantiene un Manual de la Calidad que incluye:
OBJETIVOS DE SEGURIDAD:
• GENERALIDADES:
o Características fundamentales para la utilización acorde con el destino y empleo seguro del material eléctrico.
o Colocar en lugar visible la Marca de fábrica
o Conexión segura y adecuada de todas las partes constitutivas
o Diseño y Fabricación del producto eléctrico, que Garantice la protección contra los peligros internos y externos mientras se realice el uso acorde al destino y sean objeto de un correcto mantenimiento
• PROTECCIÓN CONTRA EL PELIGRO proveniente del propio material ELÉCTRICO
o Proveer medidas de índole técnica, que protejan adecuadamente a personal y animales domésticos, ante contactos directos e indirectos
o Impedir que se produzcan temperaturas, arcos o radiaciones peligrosas.
o Proveer medidas de índole técnica, que protejan adecuadamente a personas, animales domésticos y objetos, ante peligros de naturaleza no eléctricas, que empíricamente se conozcan.
o Proveer una adecuado aislamiento para las condiciones de uso previstas.
• PROTECCIÓN CONTRA PELIGROS CAUSADOS POR INFLUENCIAS EXTERIORES.
o Proveer medidas de índole técnica que asegure que el material eléctrico empleado, responda a las exigencias mecánicas previstas con el objeto de proteger a las personas, animales domésticos y objetos.
o Proveer medidas de índole técnica que asegure que el material eléctrico empleado, responda a las exigencias no mecánicas en condiciones previstas de medio ambiente, con el objeto de proteger a las personas, animales domésticos y objetos.
o Proveer medidas de índole técnica que asegure que el material eléctrico empleado, responda en condiciones previstas de sobre carga con el objeto de proteger a las personas, animales domésticos y objetos.
1.2.- CATEGORIZACIÓN DE SUMINISTROS Y PROCESOS
1.2.1.- DESCRIPCIÓN
La categorización se realiza de acuerdo a los Requisitos de Calidad, exigibles a los tableros eléctricos, donde se definen las 4 categorías de control.
Categoría A: concierne al mayor grado de control e incluye a Productos que no son estándar y son fabricados específicamente para este contrato.
Categoría B: corresponde al grado intermedio de control e involucra productos de fabricación estándar – esenciales - con injerencia directa en la seguridad del edificio y de las personas, más los productos estándar mayores que tienen que ver con el abastecimiento normal.
Categoría C: atañe a un grado menor de control y abarca a todos los productos estándar menores, no esenciales, es decir no tienen marcada influencia en la seguridad de edificios, las personas y animales
Categoría D: corresponde a los servicios de instalación y montaje de todas las categorías anteriores.
1.2.2. CATEGORIZACIÓN:
Se consideran para los tableros eléctricos de BT, tanto los aspectos del proceso que regulan la compra de los insumos, la fabricación de los suministros específicos, el proceso de montaje como el uso continúo del tablero en su emplazamiento definitivo.
Translation - English STATEMENT OF CONFORMITY
QUALITY CONTROL MANUAL
Aimed for:
ENFORCEMENT OF DIRECTIVE 2006/95/CE from EUROPEAN PARLIAMENT AND DUE BOARD CONCERNING LEGISLATION ON ELECTRIC MATERIAL
1.- CONTROL METHODOLOGY
This document remains in compliance with APPENDIX I of Directive 2006/95/CE “Main Items on Security Objectives for Electric Material Destined to be Used within Certain Voltage Limits.”
To be applied to materials, products or equipment, service performance, executive engineering, assembly/construction processes required, as follows:
The objectives to be achieved are intended for installations/facilities to perform efficient and effective service, within aspects of contract, operation, operative security and maintenance.
1.1.- INTRODUCTION REQUIREMENTS TO BE FULFILLED, in compliance with Appendix I of Directive 2006/95/CE of the EUROPEAN PARLIAMENT AND BOARD concerning legislation upon electric material, PROYECCIÓN ELECTROLUZ SRL, establishes, documents, enforces and maintains a Quality Manual which includes:
SECURITY OBJECTIVES:
• OVERVIEW
o Essential Characteristics for usage according to purposes and safe manipulation of electric material.
o Placement in visible place of the company’s trademark.
o Safe and adequate connection of all constituent parts.
o Design and Manufacture of the electric product which guarantees protection against internal and external dangers while being used for their purpose and under proper maintenance.
• PROTECTION AGAINST DANGER resulting from ELECTRIC MATERIAL itself.
o Provide measures of technical nature which adequately protect personnel as well as domestic animals when being in either direct or indirect contact.
o Prevent the appearance of temperature, voltaic arcs or dangerous radiation.
o Provide measures of technical nature which adequately protect human beings, domestic animals and objects from dangers not related to electricity that may be known empirically.
o Provide adequate isolationism for the previewed usage conditions.
• PROTECTION AGAINST DANGERS CAUSED BY EXTERNAL INFLUENCES.
o Provide measures of technical nature to ensure the proper response of the utilized material to the expected mechanical demands with the aim of protecting human beings, domestic animals and objects.
o Provide measures of technical nature to ensure the proper response of the utilized material to non mechanical demands under agreed environmental conditions, with the aim of protecting human beings, domestic animals and objects.
o Provide measures of technical nature to ensure the proper response of the utilized material under expected overloading conditions with the aim of protecting human beings, domestic animals and objects.
1.2.- CATEGORIZATION OF SUPPLIES AND PROCESSES
1.2.1.- DESCRIPTION
Categorisation is performed according to Quality Requirements demanded to electric panels, where 4 control categories are specified.
Category A: Concerning the highest control level and including non-standard products, which are specifically manufactured for this contract.
Category B: Concerns intermediate control level and involves those products of standard –essential- manufacture with direct interference in the security of the building and human beings, plus higher standard products in connection to normal supply.
Category C: Concerns a lower quality level and comprises all minor standard products – non essential – i.e. those having no noticeable influence in the safety of buildings, human beings and animals.
Category D: Concerns installation and assembly services within all previously mentioned categories.
1.2.2. CATEGORIZATION:
These pertain to BT electric panels, within those aspects regulating the purchase of consumables, specific supplies manufacturing and the assembly process as well as the continuous use of the panel in its permanent emplacement.
English to Spanish: Technical: Oil Pump Manual General field: Tech/Engineering Detailed field: Petroleum Eng/Sci
Source text - English SECTION I
A. UNCRATING
A.l Uncrate carefully to avoid damaging the pump. Pry bars should be used with caution.
Union Pumps arc shipped with the packing removed. The packing. along with any special tools, is securely fastened to the pump. Be sure this package is not removed from the pump and mislaid or discarded with the crate. (Refer to Section ill item E)
A.2 Make a complete inspection of the pump and accessories to determine that no damage has in¬curred during shipment. If any of the equipment has been lost or damaged, notify the freight agent immediately and have him inspect the damage and make proper notation on the frciahl receipt. Then file a claim. The TRANSPORTATION COMPANY IS RESPONSIBLE for am apparent or hidden damage incurred during shipment. (If help is re¬quired. contact your nearest Union Pump Company representative or the Factory direct.)
A.3 If you have ordered spare parts or extra packing. see that they are stored in a location known to all maintenance and operating personnel.
B. LIFTING
B. 1 If it is necessary to lift the pump with a crane or chain fall. NEVER LIFT THE PIMP BY THE YOKE. LIFTING SHOULD BE DONE BY THE BASE or by BOTH FEET SIMULTANEOUSLY. All Union Pumps are accurately aligned before leaving the factory and lifting by the yoke is likely to cause misalignment and improper pump operation
C. LOCATION OF THE PUMP
C.l Locate the pump in an accessible place, so it can be inspected at regular intervals during operation. Place the pump as close to the liquid supply as possible so that suction pipe is short and direct. Provide ample head room for crane, hoist or tackle.
C.2 Whether mounted on the floor, on a foundation above the floor level, in a pit or on a structure, allow sufficient room for removal of pistons and rods, for repacking, and for replacement of other parts.
C.3 When placing a pump in a pit, provision should be made to protect the pump from water that may come into the pit from seepage or flood.
D. ERECTION AND ALIGNMENT
D.I Small pumps are lined up and rigidly bolted together before leaving the factory and do-not require the steam (drive) end to be aligned with the liquid end after being set on the foundation. Unless the pump has been damaged or somehow put out of alignment during shipment.
If the liquid end is to be removed from the steam (drive) end prior to the pump being installed on foundation it is advisable to drill a clearance hole in the yoke head toward the liquid cylinder and dowel into the cylinder. This will aid in re-alignment of the two ends together. CAUTION ! ! ! DO NOT DRILL DOWELL HOLES THROUGH THE CYLIND¬ER WALLS!
If the stuffing box(es) are removed, be sure they arc properly realigned with piston rod concentric in the box.
D.2 The erection of large pumps or others that are shipped in sections should be under the supervision of a competent erector or factory representative, as it is necessary to carefully align the liquid ends with their drive ends after they have been placed on the foundation and before tightening the foundation bolts.
D.3 On vertical pumps which are not floor mounted, arrange brackets between steam cylinder and bulk¬head (or other mounting structure) to allow for free expansion of the steam cylinder. This will prevent misalignment and excessive wear on pump parts.
D.4 IT IS IMPORTANT that all pumps be properly leveled. Extreme care should be exercised so as not to spring the unit out of alignment.
D.5 BLOW OUT STEAM INLET AND EXHAUST LINES BEFORE FINAL CONNECTIONS. (REFER TO STEAM (DRIVE) PIPING, under Heading N.
Translation - Spanish SECCIÓN I
A... DESEMBALAJE
A.l Desembalar cuidadosamente para evitar dañar la bomba. Usar con precaución las palancas de apertura.
Las Bombas Union se trasladan sin el embalaje. El embalaje junto con cualquier herramienta especial se ajusta con firmeza a la bomba. Asegurarse de que el embalaje no se pierda o descarte con el cajón luego de ser removido. (Ver Sección III ítem E)
A.2 Realizar una completa inspección de la bomba y sus accesorios para verificar que no se produjeron daños durante el envío. Si parte del equipo se encontrare faltante o dañada, notificar al agente de transporte inmediatamente y solicitarle la inspección del daño y su debido registro en el recibo de envíos. Luego presentar reclamo. La COMPAÑÍA DE TRANSPORTE ES RESPONSABLE por los daños aparentes u ocultos ocasionados durante el envío. (Para más ayuda, contactar su representante de Union Pump Company más cercano o directamente a la fábrica).
A.3 Si se hubiesen encargado repuestos o embalajes extra, asegurar su almacenamiento en un lugar conocido por el personal operativo y de mantenimiento.
B. ELEVACIÓN
B. 1 Si fuere necesario, levantar la bomba con grúa o montacargas. NUNCA LEVANTAR LA BOMBA POR EL YUGO. LA ELEVACIÓN DEBE HACERSE DESDE LA BASE o por AMBOS PIES SIMULTÁNEAMENTE. Todas las Bombas Union están perfectamente alineadas antes de abandonar la fábrica y la elevación por medio del yugo puede originar desalineación y mal funcionamiento de la bomba.
C. UBICACIÓN DE LA BOMBA
C.l Ubicar la bomba el un lugar accesible para facilitar su inspección en intervalos regulares durante la operación. Ubicar la bomba tan cerca como sea posible del suministro de líquido para que la tubería de succión sea corta y directa. Proveer de amplio espacio de altura para grúas, montacargas o poleas.
C.2 Ya sea esté montada sobre el piso, sobre cimientos por sobre el nivel del suelo, en un foso o sobre estructura, dejar suficiente espacio para la extracción de pistones y vástagos, reembalaje y recambio de partes.
C.3 Si se coloca la bomba en un foso, deben tomarse medidas de protección contra el agua que pudiera ingresar al foso por infiltración o inundación.
D. MONTAJE Y ALINEAMIENTO
D.1 Las bombas pequeñas son alineadas y rígidamente atornilladas antes de salir de fábrica y no requieren de la alineación del extremo de vapor (transmisión) con el de líquido después de su colocación en cimientos. A no ser que la bomba haya sufrido daños o se haya descalibrado durante el envío.
Si el extremo para líquido debe ser removido del extremo de vapor (transmisión) antes de instalar la bomba sobre cimientos, se recomienda perforar un hoyo de salida en el cabezal del yugo hacia el cilindro de líquido y enclavijar dentro del cilindro. Esto contribuirá al re-alinear los dos extremos juntos. ¡PRECAUCIÓN! ! ! ¡NO PERFORAR HOYOS PARA CLAVIJAS A TRAVÉS DE LAS PAREDES DEL CILINDRO!
Si la(s) caja(s) para carga son extraídas, asegurarse de que queden adecuadamente re-alineadas con pistones y vástagos concéntricos.
D.2 El montaje de bombas grandes que se transportan en secciones debe realizarse bajo la supervisión de un agente competente o representante de fábrica, ya que es necesario alinear cuidadosamente los extremos de líquido con sus extremos de transmisión luego de ubicárselos en plataforma y antes de ajustar los pernos de base.
D.3 En bombas verticales que no están montadas en piso, disponer los soportes entre el cilindro de vapor y la mampara aislante (u otra estructura montada) para permitir la expansión libre del cilindro de vapor. Esto prevendrá la desalineación y desgaste de la bomba o sus partes.
D.4 ES IMPORTANTE que todas las bombas estén adecuadamente niveladas. Debe tenerse extremo cuidado de no provocar la desalineación de la unidad.
MÉTODO ADECUADO PARA ELEVACIÓN
D.5 SOPLAR LA ENTRADA DE VAPOR Y LAS LÍNEAS DE ESCAPE ANTES DE LA CONEXIÓN FINAL. (ver TUBERÍAS DE VAPOR (TRANSMISIÓN), bajo ítems N
Italian to English: Business/Finances: Stock exchange General field: Bus/Financial Detailed field: Finance (general)
Source text - Italian FRANCOFORTE, 5 MAR - Il gruppo Adidas, nel quarto trimestre dell' anno 2007, ha realizzato un utile netto di 21 milioni di euro, superiore del 63% a quello dello stesso periodo dell' anno precedente, ma inferiore alle attese degli analisti. Nel periodo, I' utile operativo è aumentato del 18% arrivando a 61 milioni di euro. Come ha comunicato la società, il fatturato in euro è stato di 2,4 miliardi, ovvero dell' 8% superiore a quello dell' anno precedente, ma depurato degli effetti valutari risulta in aumento del 14%. Nell' anno 2007, l'utile netto è aumentato del 14% a 551 milioni di euro, il risultato operativo di 949 milioni di euro è salito dell' 8%, su un fatturato di 10,3 miliardi di euro, in crescita del 2% (depurato degli effetti valutari 7%). Il management del gruppo si è dichiarato soddisfatto dei risultati e prevede per I' anno 2008 una crescita dell' utile netto del 15% circa. (ANSA).
- MILANO, 5 MAR - Piazza Affari recupera e in avvio di seduta si mostra tonica e soprattutto, fanno sapere dalle sale
operative, con volumi decisamente superiori a quelli dell'ultimo periodo "anche se è ancora troppo presto per dire che la bufera sia
passata".
Rimbalzano tutti i titoli ieri nell' occhio del ciclone. Alitalia dopo poche decine di minuti di contrattazioni cresce del 2,03% a 0,578
euro, Fiat sale dell' 1,84 e a 13,30 recupera la soglia psicologica dei 13 euro che ieri sembrava voler cedere, mentre più leggero si
mostra il recupero di Telecom che sale dello 0,88% a 1,611.
Bene anche il settore bancario dopo le sofferenze nelle sedute di questi mesi causa mutui subprime e derivati, con Mps che cresce
dello 0,87% a 2,89 euro, la Popolare Milano che sale dello 0,56% a 7,73, Intesa SanPaolo in progresso dello 0,57% a 4,34 euro e
Unicredit in rialzo dell' 1,12% a 4,77.
Tra gli assicurativi, appare una buona giornata soprattutto per Generali che sale dello 0,65% a 27,76 con scambi molto forti, nella
galassia splende il sole anche per Mediobanca in rialzo dello 0.48% a 12,49 euro, mentre sono positivi anche i principali titoli
energetici, con Eni in progresso dello 0,80% a quota 22,64 ed Enel che sale dello 0,58% a 7,06.
Nel resto del listino in evidenza Pirelli che cresce secondo gli operatori sull'ipotesi di riacquisto della quota Tyre ( 2,64 a 0,78 euro),
il progresso maggiore è quello di Prysmian che sale di quasi il 3%, , mentre è parziale il recupero di Tiscali ( 0,47% a 1,68) dopo le
perdite di ieri.(ANSA).
Translation - English -FRANKFURT, 5 MARCH- Within the fourth quarter of the year 2007, the Adidas Group achieved a net profit of €21 million, exceeding in 63% that of the same period during the previous year, though not fulfilling the analysts’ expectations. Through that period, their operating profit increased by 18%, attaining €61 million. As reported by the company, the turnover in euros was of 2.4 billion, i.e. 8% higher than that of the previous year, which excluding currency conversion effects results in a 14% increase. During 2007, the net profit increased by 14 % to €551 million, the operating result of €949 million rose to 8% on a turnover of €10.3 billion, reflecting an increase of 2% (excluding currency effects of 7%). The group’s management welcomed the results and predicted a net profit growth of about 15% for the year 2008. (ANSA).
-MILAN, 5 MAR- Piazza Affari recovers and starts the session invigoratingly and above all –as claimed from the operational hall- with volumes distinctly higher than those of the last period "even if it is still too early to say that the storm finally passed by".
All those shares which yesterday lay in the eye of the storm now experience a rebound. Alitalia, after a few minutes of trading, grows by 2.03% to €0.578, Fiat climbs from €1.84 to €13.30, surpassing the psychological threshold of €13 which yesterday seemed willing to yield, while Telecom’s recovery comes out slighter after rising 0.88% to €1.611.
The banking sector also seems to do well after all the suffering during these months’ sessions because of subprime loans and derivatives, together with a growing MPS by 0.87% to €2.89, the Popular Bank of Milan that rises 0.56% to €7.73, Intesa Sanpaolo showing a progress of 0.57% to €4.34 and Unicredit upturning 1.12% to €4.77.
Among insurance companies, it appears to be a good day for Generali, which climbs 0.65% to €27.76 with very solid exchange rates; in this galaxy the sun shines even for Mediobanca with an upturn of 0.48% to €12.49, while the trend remains also positive for main energy corporations, with ENI reflecting progress of 0.80% per share to €22.64 and Enel rising in 0.58% to €7.06.
Within the rest of the list there appears Pirelli that, according to operators, experiences growth on the grounds of the repurchase Tyre share ( 2.64% to €0.78); the most important progress is that of Prysmian, which slopes upwards almost 3%, while Tiscali experiences partial recovery ( 0.47% to €1.68) after yesterday’s loss.
English to Spanish (Colegio de Traductores de la Pcia. de Santa Fe 2da. Circunscripción) Spanish to English (Colegio de Traductores de la Pcia. de Santa Fe 2da. Circunscripción) English to Spanish (American Translators Association) Spanish to English (Instituto de Enseñanza Superior en Lenguas Vivas "Juan Ramón Fernández") Spanish to English (American Translators Association)
Memberships
N/A
Software
Adobe Acrobat, Adobe Illustrator, Adobe Photoshop, Lingotek, Microsoft Excel, Microsoft Word, ABBYY Firereader/Web-assisted termsearchers, Other CAT tool, Powerpoint, SDLX, Trados Studio, Wordfast
Bilingual (native English/Spanish) linguist with a degree in Translation and Simultaneous Interpretation specialized in the fields of Science & Technology.
More than 18 years of experience as a freelance translator, editor, proofreader, content manager and lexicographer, along with related tasks such as internationalization, localization and content customization within the fields of Life Sciences (medicine, pharmaceuticals & biotech), finances and regulatory affairs. Furthermore, I am also able to translate/edit/proofread scientific/technical texts from Italian and Portuguese into either English or Spanish.
Summarized Work History:
Lionbridge Technologies (2011/to date)
SPANISH-ENGLISH / ENGLISH-SPANISH Translator and Language Quality Inspector.
• Life Sciences:
o Pharmaceuticals (On partnership with the European Medicines Agency): Summary of Product Characteristics, Patient Information Leaflet, Package Leaflets, Product Information Templates, Labeling of medicinal products, qualitative and quantitative formula, among others.
o Law: Clinical Trials, Informed Consent Forms, Protocols, Patient Information Sheets.
o Medicine: Clinical History reports, Medical Records, Discharge Summaries, Clinical Case Reporting, Laboratory Analysis.
o Science: Journals of Medicine, scientific magazine articles from various sources and contents.
Translatemedia, London, UK. (2009/to date)
ES-EN/IT-EN/PT-EN medical translator and proofreader.
• Life Sciences:
o Translate and proofread documents relating to life sciences and healthcare. Patient’s Information Sheets, Clinical Protocols, Informed Consent forms, Medical Records, Diagnostic Imaging reports.
o Translate and proofread content from scientific magazines, journals and articles from various sources worldwide.
• Business & Finances:
o Translate and proofread marketing, e-commerce and journalistic content.
Transperfect Translations (2006/to date)
SPANISH-ENGLISH / ITALIAN-ENGLISH Translator and Proofreader.
• Life Sciences Department: Clinical trials: protocols, informed consent forms, patient information sheet, CRO and Ethics Committee statements, Investigator’s brochure. Biochemistry: laboratory analysis, CBCs, urinalysis, biopsies, cultures, etc. Pharmaceuticals: dosage forms, product information leaflet, manufacturing standards, quality assurance. Medical records: clinical case reviews, diagnosis, treatment, progress & follow-up, discharge summaries. Diagnostic imaging: CAT scan reports, ultrasound scan reports, magnetic resonance reports, angiographies, etc. Cardiology. Neurology. Surgical procedures: angioplasty, revascularization, implants, grafting, among others.
• Legal Department: Contracts, deeds, agreements, minutes, policies, patents, protocols, employment regulations, legislative decrees, among others.
• Business and Finance Department: Balances, transaction reports, workflow charts, invoicing, stock exchange reports, import-export, customs affairs, among others.
CAPITA Translation and Interpreting, (a trading name of Applied Language Solutions Ltd.), (2012 to date)
ES-EN/IT-EN scientific translator and proofreader.
• Translate and proofread medical records, discharge summaries and clinical cases reports.
• Approval and Decisions for the conduction of Clinical Trials in both the US and the EU.
• Contracts, agreements, informed consents.
Semantix / Lingo Research Labs, Bilbao, Spain/CA, USA.(2007/2011)
ES-EN linguist/lexicographer, translator and project coordinator.
• Lexicographical resources: creation of bilingual ES-EN, EN-ES specialized dictionary and Thematic Glossaries for Dixio Desktop Online Dictionary in the fields of IT Technologies and Life Sciences.
• Project coordination: translators’ manager in the production of bilingual Spanish/English Dixio Desktop dictionaries, glossaries and lexicographical resources.
Vanesa Cresevich Translations, England, UK (2006 to date)
ES-EN, EN-ES, IT-EN, PT-EN Project Manager, Translator and proofreader.
• Project Manager in Life Sciences translation services for Spanish, English, Italian and Portuguese hospitals and clinical research organizations.
• General Medicine, Cardiology, Neurology, Nephrology, Laboratory Analysis, Surgery, Biochemistry, Oncology, Immunology, Pharmacology, Otolaryngology, among others, Clinical Trial Protocol agreements, patient’s screening and Informed Consent.
Intersphere Global Business Translation, Beverly Hills, CA, USA. (2007, 2009) IT-EN / ES-EN Localizer, Translator and project coordinator
• Translate, adapt and localize healthcare content concerning nutrition and nutritional facts from Spanish and Italian into English for Italian, Spanish and American origin products to be commercialized within multicultural communities.
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Expertise